Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Local Tremelimumab in Melanoma
NCT04274816Phase 1Completed
- Start
- Jul 2012
- Primary completion
- Feb 2014
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
01
Overview
Phase 1, open-label, single-arm trial of tremelimumab in cutaneous melanoma (CM). Primary endpoints: Number of participants with adverse events as assessed by CTCAE V3.0 at 28 days, Change in frequency of immune cell populations at 7 days and 1 more. Started Jul 2012; status: completed.
02
Drugs
tremelimumab
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on NCT04274816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04274816.